Zogenix Inc (ZGNX) Stock
ZGNX is no longer traded. Zogenix was acquired by UCB on March 4, 2022.
Each ZGNX share was exchanged for $26.00 in cash plus a contingent value right of up to $1.00. Prices on this page are historical; the last trade was March 4, 2022 at $26.68.
Zogenix stock price history
ZGNX final trading statistics
- Final close
- $26.68
- Final trading day
- Mar 4, 2022
- Market cap at delisting
- $1.50B
- Shares outstanding
- 56.23M
- Final 52-week range
- $11.03 – $26.90
- Avg. volume (final 3 mo.)
- 3,013,145
- All-time high (split-adj.)
- $61.35 · Jul 2018
- All-time low (split-adj.)
- $7.35 · Jun 2016
- Return since IPO
- -16.2%
- Beta
- 0.90
- Book value / share
- $3.19
- Price / book
- 8.36
Zogenix annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $81.69M | -$227.4M | -$4.07 |
| FY2020 | $13.64M | -$209.4M | -$3.84 |
| FY2019 | $3.65M | -$419.5M | -$9.73 |
| FY2018 | $0.00 | -$123.9M | -$3.31 |
| FY2017 | $9.82M | -$126.8M | -$4.64 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Zogenix Inc
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Zogenix stock FAQ
What happened to Zogenix stock?
Zogenix was acquired by UCB on March 4, 2022. Shareholders received $26.00 in cash plus a contingent value right of up to $1.00 for each share. ZGNX stock stopped trading on the Nasdaq, with a final close of $26.68 on March 4, 2022.
What did Zogenix shareholders receive?
Each ZGNX share was converted into $26.00 in cash plus a contingent value right of up to $1.00. The deal was valued at about $1.9 billion.
Is ZGNX stock still trading?
No. ZGNX was delisted from the Nasdaq on March 4, 2022 and no longer trades on a U.S. exchange.
What was the last price of ZGNX stock?
ZGNX closed at $26.68 on its final trading day, March 4, 2022, for a market value of about $1.50B.
What were Zogenix's revenue and earnings in its last full fiscal year?
Zogenix reported revenue of $81.69M and net income of -$227.4M in fiscal 2021, its last full year as a public company.
When did Zogenix go public?
Zogenix Inc stock began trading on November 23, 2010.